These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34773595)

  • 41. Pancreatic neuroendocrine tumors: Preoperative factors that predict lymph node metastases to guide operative strategy.
    Postlewait LM; Ethun CG; Baptiste GG; Le N; McInnis MR; Cardona K; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK
    J Surg Oncol; 2016 Sep; 114(4):440-5. PubMed ID: 27334541
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pancreatic neuroendocrine neoplasms: The latest surgical and medical treatment strategies based on the current World Health Organization classification.
    Ishida H; Lam AK
    Crit Rev Oncol Hematol; 2020 Jan; 145():102835. PubMed ID: 31864179
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CT Enhancement and 3D Texture Analysis of Pancreatic Neuroendocrine Neoplasms.
    D'Onofrio M; Ciaravino V; Cardobi N; De Robertis R; Cingarlini S; Landoni L; Capelli P; Bassi C; Scarpa A
    Sci Rep; 2019 Feb; 9(1):2176. PubMed ID: 30778137
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Calcitonin-Producing Neuroendocrine Neoplasms of the Pancreas: Clinicopathological Study of 25 Cases and Review of the Literature.
    Uccella S; Blank A; Maragliano R; Sessa F; Perren A; La Rosa S
    Endocr Pathol; 2017 Dec; 28(4):351-361. PubMed ID: 29063495
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated.
    Raj N; Valentino E; Capanu M; Tang LH; Basturk O; Untch BR; Allen PJ; Klimstra DS; Reidy-Lagunes D
    Pancreas; 2017 Mar; 46(3):296-301. PubMed ID: 27759713
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sporadic Small (≤20 mm) Nonfunctioning Pancreatic Neuroendocrine Neoplasm: is the Risk of Malignancy Negligible When Adopting a More Conservative Strategy? A Systematic Review and Meta-analysis.
    Ricci C; Casadei R; Taffurelli G; Pacilio CA; Campana D; Ambrosini V; Donatella S; Minni F
    Ann Surg Oncol; 2017 Sep; 24(9):2603-2610. PubMed ID: 28681158
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk and Predictors of Postoperative Morbidity and Mortality After Pancreaticoduodenectomy for Pancreatic Neuroendocrine Neoplasms: A Comparative Study With Pancreatic Ductal Adenocarcinoma.
    Partelli S; Tamburrino D; Cherif R; Muffatti F; Moggia E; Gaujoux S; Sauvanet A; Falconi M; Fusai G
    Pancreas; 2019 Apr; 48(4):504-509. PubMed ID: 30946244
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Time-trend and recurrence analysis of pancreatic neuroendocrine tumors.
    Kim H; Song KB; Hwang DW; Lee JH; Alshammary S; Kim SC
    Endocr Connect; 2019 Jul; 8(7):1052-1060. PubMed ID: 31252400
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Important CT and histopathological findings for recurrence and overall survival in patients with pancreatic ductal adenocarcinoma who underwent surgery after neoadjuvant FOLFIRINOX.
    Park SJ; Kim JH; Joo I; Lee KB; Han JK
    Eur Radiol; 2021 Jun; 31(6):3616-3626. PubMed ID: 33201279
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early recurrence of well-differentiated (G1) neuroendocrine liver metastasis after curative-intent surgery: Risk factors and outcome.
    Xiang JX; Zhang XF; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
    J Surg Oncol; 2018 Dec; 118(7):1096-1104. PubMed ID: 30261105
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of Outcomes Following Surgery for Locally Advanced Pancreatic Neuroendocrine Tumors.
    Titan AL; Norton JA; Fisher AT; Foster DS; Harris EJ; Worhunsky DJ; Worth PJ; Dua MM; Visser BC; Poultsides GA; Longaker MT; Jensen RT
    JAMA Netw Open; 2020 Nov; 3(11):e2024318. PubMed ID: 33146734
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Endoscopic and surgical resection of T1a/T1b esophageal neoplasms: a systematic review.
    Sgourakis G; Gockel I; Lang H
    World J Gastroenterol; 2013 Mar; 19(9):1424-37. PubMed ID: 23539431
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic indicators following curative pancreatoduodenectomy for pancreatic carcinoma: A retrospective multivariate analysis of a single centre experience.
    Petrou A; Soonawalla Z; Silva MA; Manzelli A; Moris D; Tabet PP; Friend P
    J BUON; 2016; 21(4):874-882. PubMed ID: 27685908
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The characteristics of serum lipid spectrum in PanNENs and its correlation with clinicopathological features and prognosis.
    Meng YF; Fan ZY; Yang J; Li YZ; Liu SJ; Gao CH; Gao X; Pang CY; Zhan HX
    Front Endocrinol (Lausanne); 2023; 14():1137911. PubMed ID: 37033225
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Evolution of Surgical Strategies for Pancreatic Neuroendocrine Tumors (Pan-NENs): Time-trend and Outcome Analysis From 587 Consecutive Resections at a High-volume Institution.
    Landoni L; Marchegiani G; Pollini T; Cingarlini S; D'Onofrio M; Capelli P; De Robertis R; Davì MV; Amodio A; Impellizzeri H; Malpaga A; Miotto M; Boninsegna L; Crepaz L; Nessi C; Zingaretti CC; Paiella S; Esposito A; Casetti L; Malleo G; Tuveri M; Butturini G; Salvia R; Scarpa A; Falconi M; Bassi C
    Ann Surg; 2019 Apr; 269(4):725-732. PubMed ID: 29189384
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Progesteron receptor expression in insulin producing cells of neuroendocrine neoplasms.
    Tachibana T; Kasajima A; Aoki T; Tabata T; McNamara K; Yazdani S; Satoko S; Fujishima F; Motoi F; Unno M; Sasano H
    J Steroid Biochem Mol Biol; 2020 Jul; 201():105694. PubMed ID: 32437964
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of a Palliative Surgical Approach to Stage IV Pancreatic Neuroendocrine Neoplasms with Survival: A Systematic Review and Meta-Analysis.
    Tsoli M; Spei ME; Wallin G; Kaltsas G; Daskalakis K
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32796714
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fate of Surgical Patients with Small Nonfunctioning Pancreatic Neuroendocrine Tumors: An International Study Using Multi-Institutional Registries.
    Han IW; Park J; Park EY; Yoon SJ; Jin G; Hwang DW; Jiang K; Kwon W; Xu X; Heo JS; Fu DL; Lee WJ; Bai X; Yoon YS; Yang YM; Ahn KS; Yuan C; Lee HK; Sun B; Park EK; Lee SE; Kang S; Lou W; Park SJ
    Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205787
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Clinicopathologic characteristics and prognosis of rectal neuroendocrine neoplasms].
    Liu T; Liu P; Wu T; Pan Y; Chen G; Wang P; Jiang Y; Wu Y; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1015-1019. PubMed ID: 28900992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.